Loading
Cutia Therapeutics is a biopharmaceutical firm dedicated to establishing a robust dermatology platform for addressing conditions affecting both the skin and scalp. Its comprehensive therapeutic scope encompasses various dermatological challenges, including medications for localized fat accumulation, advanced care for scalp disorders, treatments for a wide array of skin ailments, and topical pain management. Founded in 2019, the company's main headquarters are situated in Shanghai, China, complemented by additional offices located in Beijing, Wuxi, and Hong Kong.
Latest quote
HK$1.60
HK$0.00 · 0.00%
Regular session · HKT · Market data may be delayed.
Cutia Therapeutics is a biopharmaceutical firm dedicated to establishing a robust dermatology platform for addressing conditions affecting both the skin and scalp. Its comprehensive therapeutic scope encompasses various dermatological challenges, including medications for localized fat accumulation, advanced care for scalp disorders, treatments for a wide array of skin ailments, and topical pain management. Founded in 2019, the company's main headquarters are situated in Shanghai, China, complemented by additional offices located in Beijing, Wuxi, and Hong Kong.
Day range
Current HK$1.60
52-week range
Current HK$1.60
Regular session · HKT · Market data may be delayed.
Cutia Therapeutics is a biopharmaceutical firm dedicated to establishing a robust dermatology platform for addressing conditions affecting both the skin and scalp. Its comprehensive therapeutic scope encompasses various dermatological challenges, including medications for localized fat accumulation, advanced care for scalp disorders, treatments for a wide array of skin ailments, and topical pain management. Founded in 2019, the company's main headquarters are situated in Shanghai, China, complemented by additional offices located in Beijing, Wuxi, and Hong Kong.
Day range
Current HK$1.60
52-week range
Current HK$1.60
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (CNY) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 336.15M CNY | 279.62M CNY | 137.62M CNY | 11.37M CNY | 2.04M CNY |
| Cost of goods sold | 140.36M CNY | 136.15M CNY | 66.62M CNY | 3.43M CNY | 428K CNY |
| Gross profit | 195.79M CNY | 143.46M CNY | 71.01M CNY | 7.94M CNY | 1.61M CNY |
| Research and development | 148.65M CNY | 199.05M CNY | 215.71M CNY | 180.76M CNY | 110.56M CNY |
| Selling, general, and administrative | 355.75M CNY | 299.5M CNY | 255.16M CNY | 48.74M CNY | 16.55M CNY |
| Operating expenses | 504.4M CNY | 598.61M CNY | 597.98M CNY | 317.14M CNY | 181.6M CNY |
| Interest income | 6.36M CNY | 11.81M CNY | 23.41M CNY | 17.37M CNY | 6.11M CNY |
| Interest expense | 9.46M CNY | 10.86M CNY | 4.48M CNY | 1.73M CNY | 559K CNY |
| Depreciation and amortization | 30.68M CNY | 30.85M CNY | 42.48M CNY | 18.92M CNY | 9.79M CNY |
| Operating income | −308.61M CNY | −455.15M CNY | −539.65M CNY | −309.2M CNY | −179.99M CNY |
| Net income | −340.19M CNY | −433.81M CNY | −1.96B CNY | −555.84M CNY | −319.58M CNY |
Company facts updated Sep 12, 2026.
Recent quarterly results
Recent quarterly results
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
